5th Annual National Opioid Crisis Management Congress
March 15-16, 2021
(VIRTUAL CONFERENCE)

5th Annual National Opioid Crisis Management Congress

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

COVID-19 Advisory: BRI Network holds above all else, the health & safety of our attendees and their families. Our events will be hosted on a virtual platform until such time that health agencies deem travel safe. We look forward to continuing providing you with the best possible conference experience now and when we meet again in person.

About the Conference

As the world continues to battle COVID-19, there are still significant unmet needs for those fighting opioid use disorder, which is currently the number one cause of death in Americans under 50. And with the coronavirus pandemic, the crisis is expected to worsen. For those battling addiction, social distancing and quarantining have resulted in disruptions in recovery services and treatment and limited access to mental health services that patients so desperately need. Opioid use disorder affects almost every community. The misuse of and addiction to opioids—including prescription pain relievers, heroin and synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as social and economic welfare. The CDC estimates that the total economic burden of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

This conference will bring together some of the leading national experts responding to this ever-increasing public health crisis. Gain expert insight on the current landscape of opioid therapies from top thought leaders in opioid management who will share their latest research and real-world knowledge. In addition, experts at the state and federal levels providing leadership on the opioid public health crisis will explore the challenges paper writing help of using opioids to manage pain safely and effectively, new use disorder deterrents, medication-assisted treatment, federal and state regulations, practical solutions aimed at improving patient outcomes and reducing risk, and mitigating the opioid epidemic during COVID-19.

Who Should Attend?
From Hospitals/Health Systems/Health Plans/Gov’t Agencies/Law Enforcement/Substance Abuse Centers/Psychiatry

  • CEO
  • CFO
  • VP
  • Medical Directors
  • Behavioral Health Directors
  • Pharmacy Directors
  • Clinical Pharmacists
  • Social Workers
  • Outreach Coordinators
  • PDMP Directors
  • Pain Management Directors
  • Psychiatrists
  • Psychologists
  • Telehealth Directors
  • State Health Directors
  • Nursing Director
  • Emergency Room Directors
  • Substance Abuse & Prevention Directors
  • Pediatricians
  • Law Enforcement
  • Narcotic Enforcement
  • Physicians
  • Quality Improvement Director
  • Family Services Director
  • Clinical Directors
  • Investigators
  • Compliance Director
  • Correctional Coordinators

This Event Will Also be if Interest to:

  • Pharmaceutical Companies * Law Firms * Consultants * Drug Development Companies * Vendors * Solution Providers

Conference Agenda

Day One – Monday, March 15, 2021

9:45am
Opening Remarks

10:05am – 10:50am
Health Plan Interventions to Address the Opioid Crisis

The opioid crisis has been difficult for all providers and health lans. This presentation will provide insight into a managed care plan’s intervention. Participants will learn practical tips for dealing with members across products and public and commercial payers. Case examples will be used to illustrate tips. Public tools through SAMSHA and some state government entities’ will be shared.

Joyce B. Wale, LCSW
Regional Executive Director, Behavioral Health
UnitedHealthcare Community Plan

10:55am – 11:40am
Battling the Opioid Crisis During COVID-19

Before the coronavirus pandemic, the U.S. was in the midst of a different epidemic, with 100+ people a day dying of an opioid overdose. Individuals with substance use disorders (SUDs) are particularly vulnerable during the COVID-19 pandemic, and the systems of care upon which they rely have been severely constrained. In response, some regulatory policies have been eased and treatment programs have adapted. This session will examine the public health and policy implications of opioids and COVID-19.

Andrea Barthwell, MD, FASAM            
Director and Founder 
Two Dreams

11:45am – 12:30pm
Diving Deep into Tennessee’s Medicaid Opioid Strategy

In this session, presenters will focus on specific components of a statewide opioid strategy that draw on data to inform and assess clinical decision-making and supports. They will provide detailed examples of and lessons learned from collaboration between a state Medicaid agency and MCOs to implement a statewide opioid strategy. They will cover targeted supports for women of childbearing age, a comprehensive internal opioid data dashboard, and quality metrics to assess the quality of care and outcomes of MAT. These components focus on using data to inform and assess clinical decision-making and supports. As implementation of the opioid strategy has shifted over time, TennCare has worked with MCOs to expand the MAT network, including two new provider types, and to continuously improve quality metrics and the standardized program description for MAT. Presenters will address the role of collaboration in both the implementation and refinement of an active opioid strategy.

Sarah Mansouri
Director of Health Policy and Strategy
TennCare

Mary Shelton, MA
Director, Behavioral Health Operations
Division of TennCare
State of Tennessee 

12:30pm – 1:00pm
Lunch Break 

1:05pm – 1:50pm
Safer and Effective Opioid Prescribing Practices

Providers who prescribe opioids to treat chronic pain are in a key position to balance the benefits and risks of chronic opioid therapy (COT). However, providers struggle with the need to assist their patients with adequate management of chronic pain while confronting the risks associated with opioid prescribing. This session will provide recommendations for safer and more effective prescribing of opioids. Topics will include:

  • Identify opioid practice updates as outlined in the CDC opioid guidelines
  • Monitoring and documentation strategies to meet best practice standards and medical and legal requirements
  • Apply a practical framework for decision-making on the initiation, dosage modification, and when and how opioids should be discontinued
  • Tools to adequately assess risk in patients being considered for opioid therapy
  • Limiting the use of opioid prescriptions for combatting pain and recommending new treatments for pain management without the use of addictive substances

Timothy A. Munzing, MD
Family Medicine Residency Program Director
Kaiser Permanente
Medical Expert Consultant
Drug Enforcement Administration 

1:50pm – 2:50pm
Panel: The Effectiveness of Prescription Drug Monitoring Programs at Reducing Opioid-Related Harms and Consequences

In order to address the opioid crisis in the U.S., many regions have adopted preventative strategies, such as prescription drug monitoring programs (PDMPs). PDMPs are now active in most states to assist clinicians in identifying potential controlled drug misuse, diversion or excessive prescribing. However, little is still known about the ways in which they are incorporated into workflow and clinical decision making, what barriers continue to exist, and how clinicians are sharing PDMP results with their patients. This panel of leaders from PDMPs will discuss how they aim to increase patient safety by certifying that opioids are prescribed in appropriate quantities.

Panelists:

Mitchell Barnett, PharmD, MS
Associate Director – Iowa Prescription Monitoring Program
Iowa Board of Pharmacy 

Kevin Borcher
Senior Director, Pharmacy Services
PDMP Director
CyncHealth 

Kelli Ferrell, RPh, PhD
Prevention Lead Coordinator, Public Health Research
Division of Community Health Promotion
E-FORCSE Florida’s Prescription Drug Monitoring Program

2:50pm – 3:35pm
A Perspective on the Current State of the Opioid Epidemic

The U.S. is currently in the midst of an unprecedented public health crisis related to opioid misuse and dependence. This crisis had its origins in the 1990s when acceptance of prescription opioid analgesics for the management of acute and chronic pain of diverse etiology dramatically increased. The arrival of the coronavirus pandemic has provided an unanticipated haven for the already formidable opioid epidemic. COVID-19—related protective shelter-in-place orders have pushed individuals battling sobriety into isolation and have decreased access to treatment and opportunity for distraction from addictions. The speaker will present on the current opioid epidemic, how we got here, and what is being done about it.

Cara Poland, MD, Med, FACP, DFASAM
Co-Principal Investigator
Addiction Medicine
Spectrum Health Medical Group
Assistant Professor
Michigan State University College of Human Medicine

3:35pm – 4:20pm
Rapid Emergency Department Outreach (REDO): A Health Plan Response to the Opioid Crisis

The Rapid Emergency Department Outreach (REDO) pilot program outreaches to members with UPMC Health Plan insurance within 24 hours of discharge from an ED for a substance related overdose. The purpose of REDO is to provide rapid case management outreach to members to engage them in treatment and avoid repeat, and possibly, fatal overdoses. A UPMC Health Plan care manager outreach to the member within 24 hours after ED discharge. If after one telephone attempt the member is unreachable, the care manager refers the case to Community Paramedics, who attempt face-to-face outreach. The case manager and Community Paramedic work together to engage the member in treatment. Social determinants of health (SDOH) and coordination with Primary Care Physicians (PCP) and behavioral health providers/managed care organization (MCO) are core components. The members reached are more likely to have a PCP appointment within 30 days of the visit (p=0.04) and more likely to receive Medication Assisted Therapy (MAT) within 90 days of the visit. Interviews conducted with care managers found that many members were more receptive to support for things like housing and transportation than treatment. The case managers use that as an opportunity to build a relationship with them to continue the treatment conversation in the future. The next step is to expand REDO to other high-volume EDs, focusing the outreach on individuals with prior treatment history and how to navigate the barriers that COVID-19 has brought to our members with substance use seeking treatment.

Ann Giazzoni, MSW, LCSW, MBA
Senior Program Manager
PH-BH Integration
Medicaid Clinical Programs
UPMC Health Plan 

4:20pm – 5:05pm
Mindfulness-Oriented Recovery Enhancement: Clinical Trial Outcomes and Biobehavioral Mechanisms of a New Neuroscience-Based Treatment for Opioid Misuse and Chronic Pain

Opioid misuse among chronic pain patients helped to fuel the current opioid epidemic. However, to date, there are no evidence-based interventions that can simultaneously address chronic pain and opioid misuse. To meet this need, Mindfulness-Oriented Recovery Enhancement (MORE) was generated through a decade-long NIH-funded treatment development process. Rooted in affective neuroscience, MORE unites complementary aspects of mindfulness training, third-wave cognitive behavioral therapy, and principles from positive psychology into an integrative treatment designed to reduce addictive behavior, stress, and chronic pain by targeting the brain’s reward system. This session will present evidence from four randomized controlled trials (RCT) demonstrating the efficacy and biobehavioral mechanisms of MORE for reducing opioid misuse among people with chronic pain, including late-breaking outcomes from the largest clinical trial to date. Across these studies, MORE has been shown to decrease opioid misuse twice as effectively as standard psychological therapy, while at the same time reducing chronic pain symptoms, opioid craving, emotional distress, depression. These clinical outcomes last as long as nine months following the end of the MORE treatment. Findings from a series of mechanistic experiments demonstrate that MORE reduces opioid misuse by decreasing neurophysiological reactivity to drug cues and increasing neurophysiological responsivity to natural rewards, healthy pleasure, and meaningful life experiences. Given this clear demonstration of MORE’s efficacy, MORE should now be disseminated by addiction treatment, behavioral health, and primary care providers throughout the country to help stem the tide of the opioid crisis.

Eric Garland, PhD, LCSW
Distinguished Endowed Chair in Research and Associate Dean for Research
University of Utah

5:10pm
End of Day One

Day Two – Tuesday, March 16, 2021

9:10am
Recap of Day One

9:20am – 10:05am
Implementing the CDC Guidelines for Prescribing Opioids for Chronic Pain

This session will examine how to encourage careful and selective use of long-term opioid therapy in the context of managing chronic pain through:

  • An evidence-based prescribing guideline
  • Quality improvement measures to advance the integration of the CDC Guideline for Prescribing Opioids for Chronic Pain into clinical practice
  • Practice-level strategies to improve care coordination

Paul A. Sloan, MD
Professor of Anesthesiology
Vice Chair of Research
Associate Program Director, Pain Medicine Fellowship
University of Kentucky Healthcare
Editor-in-Chief
Journal of Opioid Management

10:05am – 10:50am
Telemedicine for Substance Use Disorders: Battling the Epidemic within a Pandemic

The arrival of the coronavirus has acted as a catalyst in expanding the use of telemedicine across all disease states. This has been especially true for behavioral health and substance use disorders (SUD). This presentation will discuss the evolution of telemedicine in the SUD field, including a discussion about legal and regulatory barriers that have prevented widespread adoption until recently. Challenges faced by health plans, employers, and clinics/treatment programs will be highlighted. Different organizational approaches to delivering telemedicine services will also be discussed along with a summary of outcomes that have been published to date.

Jake Nichols, Pharm.D, MBA
President and Chief Executive Officer
Professional Recovery Associates

10:55am – 11:40am
Medication-Assisted Treatment for Opioid Addiction

Physicians are encouraged both to prevent and treat opioid use disorders. Although there are FDA-approved medications to treat OUD and there is ample evidence of their efficacy, they are not used as often as they should. This session will explore these primary medications used in the treatment of OUD, and provide a framework for how to determine the optimal approach for outpatient management of OUD with medication-assisted treatments.

Manassa Hany, MD
Associate Director, Addiction Psychiatry Fellowship
Medical Director, Addiction Institute of Mount Sinai West Outpatient
Assistant Professor, Psychiatry Department
Icahn School of Medicine at Mount Sina

11:45am – 12:30pm
Pain Management During the COVID-19 Pandemic

Pain management during COVID-19 is challenging. This session will explore the proper utilization of the available resources to help with chronic pain and at increased risk of an opioid use disorder in the midst of an epidemic. Topics to be discussed will include:

  • Patient communication
  • Telemedicine
  • Unique considerations regarding pain conditions and coronavirus
  • Helping patients with increased anxiety and depression

John A. Hopper, MD, DFASAM, FAAP, FACP
Department of Internal Medicine
St. Joseph Mercy Health System
Clinical Professor
Wayne State University School of Medicine
Central Michigan University College of Medicine
Adjunct Physician Instructor
University of Michigan School of Medicine

Juliette Perzhinsky, MD, MSc, FACP
Associate Professor
Central Michigan University College of Medicine
Oak Street Health

12:30pm – 1:00pm
Lunch Break 

1:05pm – 1:50pm
Preventing Opioid Misuse and Opioid-Induced Respiratory Depression: The Pharmacist’s Role in Patient Education

Pharmacists are in an ideal position to help reverse the occurrence and potentially fatal consequences of
prescription opioid diversion. They play a vital role in providing patient education for the proper use of opioids
and have the opportunity to provide essential anticipatory guidance every time a patient receives prescription
medication. This session will examine potential interventions in which pharmacists can play a critical role, including:
– Teaching patients about the risks of opioid diversion and risk factors for opioid-induced respiratory depression
– Providing patients with information on the safekeeping and proper disposal of opioids
– Recommending naloxone for people at risk of experiencing a breathing emergency from opioids and training on proper use

Anita Jacobson, Pharm.D.
Clinical Associate Professor
The University of Rhode Island College of Pharmacy

1:55pm – 2:40pm
Addressing Patient Needs in Opioid Use Disorder

Opioid use disorder (OUD) continues to be one of the biggest public health challenges of recent history. The OUD patient presents a unique set of challenges for treatment and recovery, including trauma, polysubstance use and suicide risk. This presentation will focus on these characteristics. Data collected as part of a 5 year national outcome study will be presented as well information about the impact of COVID on OUD patients and treatment. The treatment implications to address the challenges identified in this population and support long term recovery in patients with OUD will be discussed.

Siobhan Morse, MHSA, CRC, CAI, MAC
Division Director of Clinical Services-Research and Special Projects
Behavioral Health Division
UHS

2:45pm – 3:30pm
How Do We Apply Harm Reduction in the Setting of COVID-19 and the Opioid Crisis?

Prior to COVID19, the formula for opioid treatment with methadone and buprenorphine included frequent face to face visits, within a restrictive, highly structured, and regulated system. Accompanying medication provision, such care included regular drug screens, even requiring staff to observe the client giving the specimen in the bathroom.   In response to the reality of the dangers of face-to-face contact and travel in the COVID pandemic, numerous restrictions and regulations were relaxed, such that the provision of medication treatment included higher quantities of take-home methadone or buprenorphine prescriptions, video or phone visits and decreased urine drug screen collection.  While the data is yet to be analyzed on the impact of these changes, it may provide an opportunity to rethink altogether what the system should be for provision of treatment for opioid use disorder.

Jane Liebschutz, MD, MPH, FACP
Chief, Division of General Internal Medicine
UPMC Health System

3:30pm
Conference Concludes

Featured Speakers

Michael C. White, MCJ

Michael C. White, MCJ

Director of Community Programs

Community Medical Services
Anita Jacobson, PharmC

Anita Jacobson, PharmC

Clinical Associate Professor

The University of Rhode Island College of Pharmacy
Kevin Borcher

Kevin Borcher

Senior Director, Pharmacy Services, PDMP Director

CyncHealth
Kelli Ferrell, RPh, PhD

Kelli Ferrell, RPh, PhD

Prevention Lead Coordinator, Public Health Research, Division of Community Health Promotion

E-FORCSE Florida’s Prescription Drug Monitoring Program
Manassa Hany, MD

Manassa Hany, MD

Associate Director, Addiction Psychiatry Fellowship, Medical Director, Addiction Institute of Mount Sinai West Outpatient, Assistant Professor, Psychiatry Department

Icahn School of Medicine at Mount Sinai
Sarah Mansouri

Sarah Mansouri

Director of Policy & Strategy

TennCare
Mary Shelton

Mary Shelton

Director, Behavioral Health Operations

TennCare
Siobhan Morse, MHSA, CRC, CAI, MAC

Siobhan Morse, MHSA, CRC, CAI, MAC

Division Director of Clinical Services-Research and Special Projects, Behavioral Health Division

UHS
Paul A. Sloan, MD

Paul A. Sloan, MD

Professor of Anesthesiology, Vice Chair of Research, Associate Program Director, Pain Medicine Fellowship

University of Kentucky Healthcare
Editor-in-Chief
Journal of Opioid Management
Andrea Barthwell, MD, FASAM

Andrea Barthwell, MD, FASAM

Director and Founder

Two Dreams
Mitchell Barnett, PharmD, MS

Mitchell Barnett, PharmD, MS

Associate Director – Iowa Prescription Monitoring Program

Iowa Board of Pharmacy
Cara Poland, MD, Med, FACP, DFASAM

Cara Poland, MD, Med, FACP, DFASAM

Co-Principal Investigator, Addiction Medicine

Spectrum Health Medical Group
Assistant Professor
Michigan State University College of Human Medicine
Ann Giazzoni, MSW, LCSW, MBA

Ann Giazzoni, MSW, LCSW, MBA

Senior Program Manager, PH-BH Integration, Medicaid Clinical Programs

UPMC Health Plan
Timothy A. Munzing, MD

Timothy A. Munzing, MD

Family Medicine Residency Program Director

Kaiser Permanente
Medical Expert Consultant
Jake Nichols, Pharm.D, MBA

Jake Nichols, Pharm.D, MBA

President and Chief Executive Officer

Professional Recovery Associates
Eric Garland, PhD, LCSW

Eric Garland, PhD, LCSW

Distinguished Endowed Chair in Research and Associate Dean for Research

University of Utah
Jane Liebschutz, MD, MPH, FACP

Jane Liebschutz, MD, MPH, FACP

Chief, Division of General Internal Medicine

UPMC Health System
Joyce B. Wale, LCSW

Joyce B. Wale, LCSW

Regional Executive Director, Behavioral Health

UnitedHealthcare Community Plan
Venue
(VIRTUAL CONFERENCE)
Sponsors and Exhibitors

TBA

FAQ

Are there group discounts available?

  • Yes – Register a group of 3 or more at the same time and receive an additional 10% off the registration fee

Are there discounts for Non-Profit/Government Organizations?

  • Yes – please call us at 800-743-8490 for special pricing

What is the cancellation policy?

  • Cancellations from vendors received 4 weeks prior to the event will receive a refund minus the administration fee of $225. Cancellation received less than 4 weeks prior to the event will receive a credit to a future event valid for one year. There is no fee for Hospitals/Health Systems to cancel.

Can the registration be transferred to a colleague?

  • Yes – please email us in writing at info@brinetwork.com with the colleague’s name and title
Request Brochure

Register Your Team Today!

Register Now
Ask A Question

Be A Thought Leader And Share!

Pin It on Pinterest